Biomedical Research and Therapy 2198-4093 BioMedPress 10.15419/bmrat.v5i3.426 Letter Biomedical Research and Therapy Preventive effects of statins on the incidence of liver cancer Salehiniya Hamid Allah Bakeshei Khadijah Mohammadian-Hafshejani Abdollah * Zabol University of Medical Sciences, Zabol, Iran Department of Social Medicine, School of Public Health, Dezful University of Medical Sciences, Dezful, Iran Department of Epidemiology and Biostatistics, School of Public Health, Shahrekord University of Medical Sciences, Shahrekord, Iran Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran For correspondence: amohamadii1361@gmail.com

These authors contributed equally to this work

 30 3 2018 5 3 2130 2132 26 1 2018 7 3 2018 Copyright: © The Author(s) 2017 2017 This article is published with open access by BioMedPress (BMP), Laboratory of Stem Cell Research and Application, Vietnam National University, Ho Chi Minh city, Vietnam This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Liver cancer is considered as one of the most common cancers in the world, so that it is ranked fifth in males and sixth in females in the world causing high annual costs to patients, the health system and society (Ferlay et al., 2015). The worldwide mortality rate of this disease is rising annually. This disease also has a very high fatality, so that 88% of patients in USA (Miller et al., 2016) and 90% of patients in China (Zeng et al., 2015) die of this disease in the first 5 years of its diagnosis. Therefore, it is essential to identify factors which protect against this disease. The protective effects of Statins against the cardiovascular diseases, stroke and heart attack has been proven (Tobert, 1996). Recent studies have found that Statins can also have protective effects against the cancers (Yi, Song, Wan, Chen, & Cheng, 2017). Several meta-analysis studies have explored the relationship between Statin receiving and the risk of developing liver cancer by application of randomized clinical trials, and found that the use of Statins significantly reduces the risk of liver cancer.

 Effects Liver Cancer Prevention Statin Dear Editor-in-Chief

Liver cancer is considered as one of the most common cancers in the world, so that it is ranked fifth in males and sixth in females in the world causing high annual costs to patients, the health system and society Ferlay et al., 2015. The worldwide mortality rate of this disease is rising annually. This disease also has a very high fatality, so that 88% of patients in USA Miller et al., 2016 and 90% of patients in China Zeng et al., 2015 die of this disease in the first 5 years of its diagnosis. Therefore, it is essential to identify factors which protect against this disease. The protective effects of Statins against the cardiovascular diseases, stroke and heart attack has been proven Tobert, 1996. Recent studies have found that Statins can also have protective effects against the cancers Yi, Song, Wan, Chen, & Cheng, 2017. Several meta-analysis studies have explored the relationship between Statin receiving and the risk of developing liver cancer by application of randomized clinical trials, and found that the use of Statins significantly reduces the risk of liver cancer.

The Relative Risk(RR) of liver cancer in Statin-treatment group compared with the control group was equal to RR=0.63 (Confidence interval (CI) of 95%, 0.52-0.76) in research by Singh et al. Singh, Singh, Singh, Murad, & Sanchez, 2013, RR=0.58 (CI of 95%, 0.51-0.67) in research by Shi et al. Shi, Zheng, Nie, Gong, & Cui, 2014 and RR=0.58 (CI of 95%, 0.46-0.74) in a study by Pradelli et al. Pradelli et al., 2013. Recently, Changhong et al. conducted a meta-analysis research based on Cohort studies on the dose-response relationship between the Statin receiving with incidence of liver cancer.

This study found that the relative risk of liver cancer was decrease equal to RR=0.86 (CI of 95%, 0.81-0.90) with an 50% increase in daily dose of received Statin during a year Yi et al., 2017. Therefore, based on the results of meta-analysis studies, which provide the highest level of scientific inferences, it can be argued that Statins can have protective effects against the incidence of liver cancer. Furthermore, according to the proof of dose-response relationship between the received Statin and the incidence of liver cancer, the observed relationship can be considered as a causal association.

 Abbreviations

CI :Confidence Interval

RR: Relative Risk

 References J. Ferlay I. Soerjomataram R. Dikshit S. Eser C. Mathers M. Rebelo F. Bray Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 International Journal of Cancer 2015 136(5) E359 E386 10.1002/ijc.29210 25220842 K. D. Miller R. L. Siegel C. C. Lin A. B. Mariotto J. L. Kramer J. H. Rowland A. Jemal Cancer treatment and survivorship statistics, 2016 CA: a Cancer Journal for Clinicians 2016 66(4) 271 289 10.3322/caac.21349 27253694 D. Pradelli D. Soranna L. Scotti A. Zambon A. Catapano G. Mancia G. Corrao Statins and primary liver cancer: A meta-analysis of observational studies European Journal of Cancer Prevention 2013 22(3) 229 234 10.1097/CEJ.0b013e328358761a 23010949 M. Shi H. Zheng B. Nie W. Gong X. & Cui Statin use and risk of liver cancer: An update meta-analysis BMJ Open 2014 4(9) e005399 10.1136/bmjopen-2014-005399 25227628 S. Singh P. P. Singh A. G. Singh M. H. Murad W. & Sanchez Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis Gastroenterology 2013 144(2) 323 332 10.1053/j.gastro.2012.10.005 23063971 J. A. Tobert Carcinogenicity of lipid-lowering drugs Journal of the American Medical Association 1996 275(19) 1480 1482 10.1001/jama.1996.03530430023029 8622219 C. Yi Z. Song M. Wan Y. Chen X. & Cheng Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies Medicine 2017 96(27) e7435 10.1097/MD.0000000000007435 28682909 H. Zeng R. Zheng Y. Guo S. Zhang X. Zou N. Wang X. Q. Yu Cancer survival in China, 2003-2005: A population-based study International Journal of Cancer 2015 136(8) 1921 1930 10.1002/ijc.29227 25242378